Gland Pharma Reports Strong Q1 Results with Revenue Up 20% YoY, PAT Jumps 47%

Gland Pharma Reports Strong Q1 Results with Revenue Up 20% YoY, PAT Jumps 47%​

Gland Pharma Limited, an injectable-focused pharmaceutical company, has announced its financial results for the first quarter and year ended June 30, 2026. The company reported robust growth across key metrics, including a 20% increase in quarterly revenue and a significant 47% jump in Profit After Tax (PAT) on a year-on-year basis.

The consolidated financial performance showed strong momentum, driven by the company's CDMO and B2B business models. Revenue from operations stood at ₹18,003 million for the quarter. The results highlighted significant increases across profitability indicators.

Consolidated Financial Performance Snapshot​

The first-quarter results demonstrated strong margin expansion and profitable growth. Key financial figures are summarized below:


The growth was primarily driven by the company's business segments. The CDMO segment contributed 50% of the total revenue and saw a 20% year-on-year increase. Concurrently, the B2B business also accounted for 50% of revenues and grew by 19% year-on-year.

Operational and Business Updates​

Gland Pharma highlighted major strides in its product development pipeline during the quarter. The company launched four molecules in the U.S., including Multi-Vitamin and Leucovorin calcium. In terms of regulatory progress, three ANDAs were filed, and seven were approved in Q1 FY27. These developments bring the cumulative total to 389 ANDA filings in the U.S., with 342 approved and 47 pending.

The company's focus on complex injectables remains central to its long-term growth strategy. Six products have already been launched from the in-house complex pipeline, with three more in line for approval. Furthermore, the company is advancing its Ready-to-Use (RTU) bags portfolio; 21 infusion bag products were filed, 18 received approval, and 11 are currently under development. This RTU bag portfolio addresses a market opportunity estimated at $644 million in the U.S.

Strategic collaborations are also advancing the company's future growth prospects. A CDMO partnership with a Global Pharmaceutical Company holds an annualized revenue potential of USD 90-100 million upon commercialization, with technology transfer activities planned for completion within two years and revenues expected to commence from calendar year 2029. Additionally, Gland Pharma established a long-term strategic collaboration with Neuland Laboratories for the manufacturing of sterile APIs for microparticle depot products, and an in-licensing agreement was signed with a China-based development company for a niche liposomal product targeted at U.S. and European markets.

Market Performance Analysis​

The company's market penetration showed strong performance across key global regions. The USA remains a dominant contributor to revenue, showing 32% year-on-year growth. Europe also contributed strongly with a 20% YoY increase in revenue. India saw a healthy 12% growth in the B2B segment.

In contrast, the Other Core Markets (Canada, Australia and New Zealand) experienced a decline of 28% year-on-year. The Rest of the World division reported a 2% growth for the quarter.

GLAND Stock Price Movement​

Today, shares of Gland Pharma Limited edged higher to close at ₹2667.3, after rallying 2.65% in a positive session. The stock closed near its high for the day, demonstrating strong investor interest with total traded volume reaching 720,772 shares.